GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » Cash Ratio

China Isotope & Radiation (HKSE:01763) Cash Ratio : 0.68 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. China Isotope & Radiation's Cash Ratio for the quarter that ended in Dec. 2023 was 0.68.

China Isotope & Radiation has a Cash Ratio of 0.68. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for China Isotope & Radiation's Cash Ratio or its related term are showing as below:

HKSE:01763' s Cash Ratio Range Over the Past 10 Years
Min: 0.51   Med: 0.73   Max: 1.19
Current: 0.68

During the past 9 years, China Isotope & Radiation's highest Cash Ratio was 1.19. The lowest was 0.51. And the median was 0.73.

HKSE:01763's Cash Ratio is ranked worse than
63.51% of 855 companies
in the Medical Devices & Instruments industry
Industry Median: 1.23 vs HKSE:01763: 0.68

China Isotope & Radiation Cash Ratio Historical Data

The historical data trend for China Isotope & Radiation's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Isotope & Radiation Cash Ratio Chart

China Isotope & Radiation Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only 0.93 0.92 0.68 0.73 0.68

China Isotope & Radiation Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 0.58 0.73 0.54 0.68

Competitive Comparison of China Isotope & Radiation's Cash Ratio

For the Medical Devices subindustry, China Isotope & Radiation's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Isotope & Radiation's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's Cash Ratio distribution charts can be found below:

* The bar in red indicates where China Isotope & Radiation's Cash Ratio falls into.



China Isotope & Radiation Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

China Isotope & Radiation's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=3142.481/4652.849
=0.68

China Isotope & Radiation's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=3142.481/4652.849
=0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Isotope & Radiation  (HKSE:01763) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


China Isotope & Radiation Cash Ratio Related Terms

Thank you for viewing the detailed overview of China Isotope & Radiation's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


China Isotope & Radiation (HKSE:01763) Business Description

Traded in Other Exchanges
N/A
Address
No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines